Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 9/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 8/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 3/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 1.00 |
| ▸ | F10 | P00742 | 1/20 | 0.79 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.78 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415635 | 0.88 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL19831685 | 0.88 | HDAC1 (0.78) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL8401704 | 0.87 | HDAC1 (0.89) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4263626 | 0.86 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4263628 | 0.86 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL1066040 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL1064720 | 0.86 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL1065292 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL2411022 | 0.86 | HDAC1 (0.75) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL3821744 | 0.85 | F10 (0.93) | HDAC1HDAC3HDAC2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3062784-B1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2020-12-23 | — | — | EP | claimed |
| CN-105682655-B | Antimicrobial compounds | 阿克塞利亚制药公司 | 2020-03-27 | — | — | CN | claimed |
| US-9957226-B2 | Antimicrobial compounds | AKTHELIA PHARMACEUTICALS (IS) | 2018-05-01 | — | — | US | claimed |
| US-20160257642-A1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2016-09-08 | — | — | US | claimed |
| CN-105682655-A | Antimicrobial compounds | 阿克塞利亚制药公司 | 2016-06-15 | — | — | CN | claimed |
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3062784-B1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2020-12-23 | — | — | EP | disclosed |
| EP-3062784-B1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2020-12-23 | — | — | EP | disclosed |
| CN-105682655-B | Antimicrobial compounds | 阿克塞利亚制药公司 | 2020-03-27 | — | — | CN | disclosed |
| US-9957226-B2 | Antimicrobial compounds | AKTHELIA PHARMACEUTICALS (IS) | 2018-05-01 | — | — | US | disclosed |
| US-9957226-B2 | Antimicrobial compounds | AKTHELIA PHARMACEUTICALS (IS) | 2018-05-01 | — | — | US | disclosed |
| US-9957226-B2 | Antimicrobial compounds | AKTHELIA PHARMACEUTICALS (IS) | 2018-05-01 | — | — | US | disclosed |
| WO-2015063694-A1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015063694-A1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2015-05-07 | — | — | WO | disclosed |
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1517897-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000817-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 2/4885 |
| US-20160257642-A1 | ANTIMICROBIAL COMPOUNDS | BECN1, SQSTM1, ATG7 | HDAC1 16/4885HDAC3 4/4885HDAC2 23/4885 |
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | HDAC1 1422/4885HDAC3 633/4885HDAC2 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.